TLDR:
- Nebu-Flow, a Glasgow-based nebulizer platform provider, raised an additional $5.9M in funding.
- The funding round was led by SCVC and supported by various investors including Scottish Enterprise and Foresight WAE Technology.
Nebu-Flow, a Glasgow, Scotland, UK-based provider of a nebulizer platform, has raised an additional $5.9M in funding. The round was led by SCVC and supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund. The company plans to use the funds to accelerate the development of inhaled drugs for patients with respiratory disorders. Led by Dr Elijah Nazarzadeh (CEO) and Dr John Pritchard (Chair), Nebu-Flow is focused on developing a new generation of nebulizers to enable inhalation delivery of life-changing treatments.
Dr. Elijah Nazarzadeh, the CEO of Nebu-Flow, expressed excitement about the investment, stating that their mission is to revolutionize respiratory drug delivery. The funding will help accelerate their development activities to position the company for inhalation delivery of RNA-based formulations. With the support of SCVC and other investors, Nebu-Flow looks forward to final product development and commercialization stages.
Overall, the additional funding secured by Nebu-Flow will enable the company to further its innovative work in respiratory drug delivery and bring new treatment options to patients with respiratory disorders. The support of investors like SCVC, Scottish Enterprise, and others highlights the potential impact of Nebu-Flow’s cutting-edge nebulizer technology in the healthcare industry.
